Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: An analysis of the TAX 324 trial

Cancer

Volumn 118, Issue 7, 2012, Pages 1811-1817

  Wu, Yin ^a   Posner, Marshall R ^b   Schumaker, Lisa M ^a   Nikitakis, Nikolaos ^a   Goloubeva, Olga ^a   Tan, Ming ^a   Lu, Changwan ^a   Iqbal, Sana ^a   Lorch, Jochen ^b   Sarlis, Nicholas J ^c   Haddad, Robert I ^b   Cullen, Kevin J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SANOFI   (France)

Author keywords

In human papilloma virus; Negative; Oropharyngeal cancer; Prognostic markers

Indexed keywords

BETA TUBULIN II; CISPLATIN; DOCETAXEL; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; MEMBRANE PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84858699459     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26485     Document Type: Article

References (44)

1. American Cancer Society. Cancer Statistics 2009 Presentation. Atlanta, GA: American Cancer Society; 2009. Available at http://www.cancer.org. Accessed April 30, 2011.
2. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
3. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272. (Pubitemid 24057404)
4. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000;83:1594-1598. (Pubitemid 32001699)
5. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715. (Pubitemid 350005152)
6. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704. (Pubitemid 350005151)
7. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92: 709-720. (Pubitemid 30365531)
8. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-475. (Pubitemid 40270113)
9. El-Mofty SK, Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:339-345. (Pubitemid 43303813)
10. Martinez I, Wang J, Hobson KF, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007;43:415-432. (Pubitemid 46123982)
11. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121: 1813-1820. (Pubitemid 47417302)
12. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269. (Pubitemid 351480538)
13. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
14. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer 2005;103:1843-1849. (Pubitemid 40563256)
15. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619. (Pubitemid 351264356)
16. Sturgis EM, Dahlstrom KR. Inaccurate assumptions about oropharyngeal cancer [serial online]. BMJ 2009;339:b4525.
17. Cullen KJ, Schumaker L, Nikitakis N, et al. β-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 2009;27:6222-6228.
18. Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-4104. (Pubitemid 30013791)
19. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168. (Pubitemid 28144151)
20. Heagerty PJ. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105. (Pubitemid 40380968)
21. Posner MR, Lorch J, Goloubeva O, et al. Oropharynx cancer (OPC) in TAX 324: human papillomavirus (HPV) and survival [abstract]. J Clin Oncol 2010;28(15s). Abstract 5525.
22. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2009;2:776-781.
23. Nishimura T, Newkirk K, Rasmussen A, et al. Glutathione S-transferase expression predicts response to cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:1859-1865. (Pubitemid 26384153)
24. Cullen KJ, Newkirk KA, Schumaker LM, et al. Glutathione- S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003;63:8097-8102. (Pubitemid 37549452)
25. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Engl J Med 2001;345:1890-1900. (Pubitemid 33716564)
26. Temam S, Flahault A, Perie S, et al. P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-394. (Pubitemid 30056429)
27. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-1473. (Pubitemid 30205392)
28. Perrone F, Bossi P, Cortelazzi B, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010;28:761-766.
29. Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 2001;59:179-185. (Pubitemid 32452311)
30. Pena JC, Thompson CB, Recant W, et al. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-170. (Pubitemid 29031371)
31. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-344. (Pubitemid 36249816)
32. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006;24:2606-2611. (Pubitemid 46622080)
33. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636. (Pubitemid 46631302)
34. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16, and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120:1731-1738. (Pubitemid 46399359)
35. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL, and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-3137.
36. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26:3138-3146.
37. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009;140:228-234.
38. Hafkamp HC, Manni JJ, Speel EJ. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 2004;124:520-526. (Pubitemid 38797618)
39. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-813. (Pubitemid 32783066)
40. Peltenburg LT. Radiosensitivity of tumor cells. Oncogenes and apoptosis. Q J Nuc Med 2000;44:355-364. (Pubitemid 32192912)
41. Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-6651. (Pubitemid 44876832)
42. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of treatment modality? Int J Cancer 2009;126:1256-1262.
43. Ukpo OC, Pritchett CV, Lewis JE, et al. Human papillomavirus-associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otol Rhinol Laryngol 2009;118:368-373.
44. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-1548. (Pubitemid 29457958)